Avilex Pharma ApS is focused on developing innovative neuroprotectants, with its lead candidate, AVLX-144, being a dimeric peptide-like drug designed to inhibit the postsynaptic density protein 95 (PSD-95). This compound targets two PDZ domains of PSD-95 simultaneously, which is crucial for bridging the NMDA receptor and neuronal nitric oxide synthase, thereby enhancing neuroprotective properties. AVLX-144 has shown promising results in preclinical studies and has successfully completed a Phase 1 clinical trial, demonstrating good tolerability and safety, which sets the stage for further clinical development aimed at treating acute neurological conditions such as acute ischemic stroke and subarachnoid hemorrhage.

The development of AVLX-144 is supported by a robust scientific foundation, leveraging a clinically validated mechanism of action. The compound's design offers several advantages, including high affinity for PSD-95 and increased stability, which are essential for its efficacy in vivo. Avilex Pharma is also working on a pipeline of neuroprotectants targeting various unmet medical needs, indicating a commitment to addressing significant health challenges associated with acute neurological conditions. The company has received funding from notable organizations, including the Danish Innovation Fund and the Wellcome Trust, to support its research and development efforts.

Denmark

Avilex Pharma is a clinical stage company supported by venture capital and national foundations, with experienced researchers and pharmaceutical veterans.

Ischemic stroke is the second leading cause of death and a major cause of disability. Avilex Pharma investigates a novel principle in treatment to meet this major medical need.

Avilex Pharma ApS

Company Details